Evaxion Biotech A/S has received funding from the Danish Innovation Fund to further develop their AI platform RAVEN to rapidly respond against future corona virus pandemics – from initial discovery to first in human trials in as little as 13 weeks. During those 13 weeks SB3000 intends to develop and validate a tailored μLOT continuous manufacturing process for the vaccine at commercial scale. Being modular and easily transportable, the μLOT enabled production units can be deployed to sites...